Skip to main content
Erschienen in: Investigational New Drugs 1/2009

01.02.2009 | SHORT REPORT

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

verfasst von: Thomas W. Flaig, Fernando J. Kim, Francisco G. La Rosa, Kathryn Breaker, Jonathan Schoen, Paul D. Russ

Erschienen in: Investigational New Drugs | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Excerpt

A woman with renal cell carcinoma (RCC) presented with sudden right sided flank pain and anuria. Two years earlier she was diagnosed with RCC clear cell type and had a left-sided nephrectomy performed at that time. Her initial staging evaluation revealed multiple pulmonary nodules consistent with metastatic disease and she was started on sorafenib therapy. She remained on this therapy for 9 months, but was then found to have progressive disease and high-dose interleukin-2 (IL2) was initiated. The patient developed bilateral pulmonary edema during her initial course of IL2 which was believed to be secondary to IL2-induced capillary leak and required endotracheal intubation. Accordingly, IL2 was abandoned without completing a full course and treatment with sunitinib (50 mg daily for 4 weeks followed by a 2 week break) was pursued. …
Literatur
3.
Zurück zum Zitat Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535 Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535
7.
Zurück zum Zitat Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef
8.
Zurück zum Zitat Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010 Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010
9.
10.
Zurück zum Zitat Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019 DOI 10.1200/JCO.2007.14.9930 PubMedCrossRef Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019 DOI 10.​1200/​JCO.​2007.​14.​9930 PubMedCrossRef
11.
Zurück zum Zitat Garcia AA, Hirte H, Fleming F et al (2008) Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium. J Clin Oncol 26:76–82 DOI 10.1200/JCO.2007.12.1939 PubMedCrossRef Garcia AA, Hirte H, Fleming F et al (2008) Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium. J Clin Oncol 26:76–82 DOI 10.​1200/​JCO.​2007.​12.​1939 PubMedCrossRef
12.
Zurück zum Zitat Berger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165–5177 DOI 10.1200/JCO.2007.11.5345 CrossRef Berger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165–5177 DOI 10.​1200/​JCO.​2007.​11.​5345 CrossRef
15.
Zurück zum Zitat Heng Y, Schuffler MD, Haggitt RC et al (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758PubMed Heng Y, Schuffler MD, Haggitt RC et al (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758PubMed
16.
Zurück zum Zitat Asmis TR, Chung KY, Teitcher JB et al (2007) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96 DOI 10.1007/s10637-007-9094-z PubMedCrossRef Asmis TR, Chung KY, Teitcher JB et al (2007) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96 DOI 10.​1007/​s10637-007-9094-z PubMedCrossRef
Metadaten
Titel
Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma
verfasst von
Thomas W. Flaig
Fernando J. Kim
Francisco G. La Rosa
Kathryn Breaker
Jonathan Schoen
Paul D. Russ
Publikationsdatum
01.02.2009
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 1/2009
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-008-9146-z

Weitere Artikel der Ausgabe 1/2009

Investigational New Drugs 1/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.